This the fourth instalment of a 5-part webinar series between the British Neuroscience Association and the Psychiatry Consortium.
Psychiatric drug discovery must be a truly collaborative process if it is to be successful. All too often industry and academia work exclusively, developing transformative work in isolation of each other and only building alliances at a later stage when necessary. Cross-disciplinary partnerships cultivated earlier in the process can take a project in a whole new direction, for the benefit of those working on the science, for the patient and the investor.
This webinar was originally streamed live via Zoom on Tuesday 8th March 2022, 3-4pm (GMT) and explored the drug discovery pipeline from the perspective of figures within the pharmaceutical industry.
Host organisations: BNA and Psychiatry Consortium
Chair: Marianthi Papakosta (Takeda)
Speakers: Aslihan Selimbeyoglu (Compass Pathways) Jeanne Bolger (J&J Innovation)